Current And Emerging Pharmacological Strategies In The Management Of Diabetes Mellitus

[1] Jaya,[2]Dr. Sunita Dhiman*,[3]Dr. Jyoti Gupta, [4] Panshul Sharma

[1]Student, [2] Associate Professor,[3] Professor, [4] Assistant Professor

[1]IEC School of Pharmacy,

[1]IEC University, Himachal Pradesh, Baddi, India

ABSTRACT

Diabetes mellitus is a chronic metabolic disorder defined by elevated blood glucose resulting from defects in insulin secretion, insulin action, or both. Typical symptoms encompass polyuria, polydipsia, polyphagia, sudden weight loss, lethargy, and a higher susceptibility to infections. Prompt diagnosis via clinical indicators and laboratory assessments, such as fasting plasma glucose and HbA1c, is crucial for preventing systemic complications. Therapeutic approaches have evolved from conventional medications like metformin, sulfonylureas, and insulin to innovative classes including GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Furthermore, breakthroughs in immunotherapy and regenerative science—specifically stem cell-derived beta cell replacement and immune modulation—provide transformative potential, particularly for managing type 1 diabetes. By 2025, global projections suggest nearly 589 million adults will live with diabetes, facing substantial risks of morbidity and mortality from vascular issues. This burden is disproportionately heavy in low- and middle-income nations; India, for instance, supports nearly 90 million cases marked by significant regional variance. Modern treatments strive for enhanced efficacy, safety, and patient compliance through developments like oral incretin mimetics and automated insulin delivery (artificial pancreas) systems. Nevertheless, hurdles regarding affordability, healthcare access, and long-term safety profiles remain. Despite these obstacles, advancing scientific insights and optimized care models offer a pathway toward better prevention, management, and even disease reversal. Sustained multidisciplinary cooperation among researchers, policymakers, and clinicians is vital to mitigating the worldwide diabetes crisis.

KEYWORDS: Diabetes, Insulin, Metformin, Pancreas, Beta cells, IDDM, NIDDM.

INTRODUCTION

Diabetes mellitus (DM) is a persistent metabolic condition defined by high blood sugar levels resulting from inadequate insulin production or impaired insulin function [1]. The name originates from the Greek word for "siphoning through" and the Latin term for "honeyed," referencing glucose in the urine [2]. The pancreas is the primary regulator of glucose via insulin secretion [3]; the 1922 breakthrough by Banting and Best in isolating insulin revolutionized clinical management [4].

Global prevalence currently stands at approximately 537 million adults, with estimates reaching 783 million by 2045 [5]. This surge is largely fueled by aging populations, rapid urbanization, physical inactivity, and rising obesity rates [6]. Left unmanaged, diabetes is a primary driver of heart disease, renal failure, vision loss, and lower-limb amputations [7].

The disease is categorized into two primary forms: Type 1 (T1DM), an autoimmune disorder leading to total insulin deficiency [8][9], and Type 2 (T2DM), which involves a combination of insulin resistance and declining beta-cell performance [10][11]. Additionally, gestational diabetes (GDM) develops during pregnancy, presenting health risks for both the mother and the infant [12].



Fig.1. Types of Diabetes Mellitus

T1DM is triggered by the immune system attacking beta cells [13], whereas T2DM stems from a blend of genetic predispositions and environmental triggers that impair insulin sensitivity [14]. Chronic hyperglycemia further induces oxidative stress and systemic inflammation, worsening the metabolic state [15].

Clinical identification relies on fasting glucose levels, oral glucose tolerance assessments, and HbA1c measurements, guided by ADA and WHO protocols [16]. Prompt screening allows for early lifestyle interventions and pharmacological treatment to mitigate long-term damage [17].

India has emerged as a critical hub for the condition, with more than 100 million cases [18]. This is attributed to shifting dietary patterns and reduced exercise associated with urban living [19]. Addressing this requires customized public health policies that account for regional genetic and socioeconomic diversity [20].

Chronic complications involve damage to the kidneys (nephropathy), eyes (retinopathy), and nerves (neuropathy), alongside macrovascular risks such as stroke and myocardial infarction [21]. Effective care demands a holistic approach focusing on glucose, blood pressure, and cholesterol management [22].

Modern pharmacological advancements, specifically SGLT2 inhibitors and GLP-1 receptor agonists, now provide significant renal and cardiovascular protection [23]. Ongoing investigations into gene therapy, immunotherapy, and the regeneration of beta cells represent the next frontier of treatment [24].

Ultimately, diabetes remains a multifaceted global challenge. Reducing its impact necessitates a deep understanding of its pathology, early detection, and the implementation of precision medicine.

CLASSIFICATIONS OF DIABETES MELLITUS

Diabetes mellitus (DM) represents a heterogeneous group of metabolic conditions characterized by chronic hyperglycemia stemming from defects in insulin production, insulin sensitivity, or a combination of both [25]. Distinguishing between these types is vital for tailoring clinical management and determining prognosis, as each variant is rooted in unique biological pathways.

TYPE 1 DIABETES MELLITUS (T1DM)

Representing 5–10% of global cases, T1DM is caused by the autoimmune-mediated destruction of pancreatic β-cells, leading to a total lack of insulin [26]. This process typically involves environmental triggers acting on a genetic predisposition. While historically associated with youth, T1DM can manifest at any stage of life [27].

The clinical presentation is often acute, featuring polyuria, polydipsia, rapid weight loss, and potentially life-threatening diabetic ketoacidosis (DKA) [28]. Because the body cannot produce insulin, daily exogenous insulin therapy is mandatory for survival [29]. Modern diagnostics can identify a pre-symptomatic stage where specific autoantibodies are present before blood sugar rises significantly [30].

TYPE 2 DIABETES MELLITUS (T2DM)

T2DM accounts for roughly 90% of the diabetic population and is defined by insulin resistance paired with a gradual decline in β-cell compensation [31]. Risk factors include obesity, physical inactivity, advancing age, and heredity [32]. Because it develops slowly, many individuals remain undiagnosed for years until complications or routine screenings occur [33].

This type is often a component of metabolic syndrome, characterized by hypertension, dyslipidemia, and abdominal obesity, all of which heighten cardiovascular danger [34]. The pathology is complex, involving excessive hepatic glucose production and impaired incretin effects [35]. While management starts with lifestyle changes and drugs like metformin, newer options like GLP-1 agonists and SGLT2 inhibitors are now frequently utilized to provide extra organ protection [36].

GESTATIONAL DIABETES MELLITUS (GDM)

GDM is a form of glucose intolerance first recognized during pregnancy, affecting roughly 7% of pregnancies worldwide [37]. It occurs when placental hormones induce insulin resistance that the mother's β-cells cannot overcome [38]. GDM carries risks such as neonatal hypoglycemia, macrosomia (large birth weight), and an increased likelihood of C-section deliveries.

Beyond the immediate pregnancy, women with GDM have a significantly higher risk of transitioning to T2DM later in life. Their offspring also face increased risks of obesity and metabolic issues [39]. Standard screening involves an oral glucose tolerance test (OGTT) performed between the 24th and 28th weeks of pregnancy [40].

INDICATORS OF DIABETES MELLITUS

Diabetes mellitus (DM) refers to a cluster of metabolic ailments defined by chronic hyperglycemia originating from defects in insulin production or performance. While clinical presentations differ based on

the specific type and duration of the condition, symptoms are fundamentally driven by high blood sugar and its widespread systemic impact [41].

Polyuria and Polydipsia When plasma glucose exceeds the renal threshold—approximately **180 mg/dL**—the kidneys cannot reabsorb the excess, causing glucose to enter the urine and pull water along with it. This results in frequent urination (polyuria). The subsequent dehydration stimulates the brain's thirst centers, leading to excessive fluid intake (polydipsia) [42]. These represent the most classic early indicators for all forms of the disease [43].

Polyphagia and Weight Loss Because cells cannot effectively absorb glucose for fuel, the body enters a state of perceived starvation despite high blood sugar, triggering intense hunger (polyphagia). In Type 1 cases, the lack of insulin forces the body to metabolize fat and muscle tissue, causing rapid weight loss [44][45]. For those with Type 2, significant weight reduction is rarer in the initial stages but can emerge as insulin production fails over time [46].

Lethargy and Weakness Poor glucose utilization translates to a lack of cellular energy. This manifests as persistent fatigue, a sense of weakness, and a noticeable drop in physical stamina [47].

Visual Impairments Elevated glucose levels create an osmotic shift that causes the lens of the eye to swell, resulting in blurred vision. If hyperglycemia remains chronic, it can lead to diabetic retinopathy, characterized by vascular microaneurysms and hemorrhages that threaten permanent sight [48].

Infections and Slow Recovery High sugar levels hinder white blood cell (neutrophil) efficiency and compromise circulation. This makes the body more prone to candidiasis, urinary tract issues, and skin infections, while also slowing the rate of wound healing [49]. These complications are particularly severe in cases of poor glycemic control [50].

Neuropathic Signs Damage to peripheral nerves often results in "pins and needles" sensations, numbness, burning pain, or a total loss of feeling, primarily in the lower extremities. These neuropathic changes significantly increase the danger of unnoticed injuries, foot ulcers, and potential amputations [51].

Additional Symptoms

Some individuals may experience less typical symptoms such as dry mouth (xerostomia), itchy skin (pruritus), mood changes like irritability, and cognitive disturbances related to fluctuating blood sugar levels [56].

GLOBAL IMPACT OF DIABETES MELLITUS

Prevalence and Growth Patterns

Diabetes mellitus has emerged as one of the most fast-moving threats to international public health. Data from the 2025 International Diabetes Federation (IDF) Diabetes Atlas (11th edition) indicates that roughly **589 million adults** (ages 20–79) were living with the condition in 2024, accounting for approximately 11.1% of the world's adult population [57]. Projections suggest this figure will climb to 853 million by 2050, underscoring the intensifying pressure on global health systems [58].

Since the turn of the century, the global incidence of diabetes has almost doubled. This surge is primarily driven by demographic aging, rapid urban development, modernized dietary habits, and escalating levels of obesity and sedentary behavior—particularly within low- and middle-income countries (LMICs) [59].

Currently, nearly 80% of the diabetic population lives in LMICs, regions where medical infrastructures frequently face significant challenges in providing consistent chronic disease management [60].

India, China, and the United States remain the nations with the largest total populations affected by the disease [61]. While the African continent presently maintains a comparatively lower prevalence rate of around 4.5%, it is forecasted to undergo the most dramatic relative spike—potentially rising by 129%—by the year 2045 [62].

MORTALITY AND MORBIDITY

Diabetes is a primary driver of global fatality rates, responsible for more than 3.4 million deaths in 2024—a staggering rate of one death every nine seconds [63]. Cardiovascular disease continues to be the most frequent cause of death among those with the condition [64]. Furthermore, long-term complications including renal failure, vision loss, lower-limb amputations, and nerve damage severely diminish quality of life and intensify the demand for medical services [65].

A major public health challenge is the prevalence of undiagnosed cases; worldwide, approximately 50% of adults living with diabetes are oblivious to their status [70]. Such delays in identification result in more severe physiological damage and escalated medical expenses upon eventual diagnosis. In addition to direct healthcare costs, the disease places a heavy strain on society through diminished workplace productivity and weakened economic growth [71].

ECONOMIC BURDEN

By 2024, international healthcare expenditures related to diabetes surpassed USD 1 trillion, representing a massive 338% surge over the last 17 years [72]. These ballooning costs are overwhelming healthcare infrastructures globally and creating significant obstacles to attaining universal health coverage. Interestingly, while the majority of patients reside in low- and middle-income countries (LMICs), high-income nations still incur the highest per capita spending on the disease [73].

HEALTH SYSTEMS IMPACT AND RESPONSE

Effective diabetes management requires a transition from short-term, episodic care to a comprehensive, long-term chronic disease management model. This approach emphasizes coordinated multidisciplinary care, patient education, continuous glucose monitoring, and sustained access to essential medicines and healthcare technologies [74]. Such integrated care models are critical for improving treatment adherence, preventing complications, and enhancing patient outcomes.

In response to the rising diabetes burden, many countries have implemented national prevention and control programs. International health agencies advocate for early diagnosis, promotion of healthy lifestyles, and reduction of modifiable risk factors such as obesity and physical inactivity [75]. Additionally, the growing use of digital health tools and telemedicine has improved access to diabetes care, particularly in resource-limited and underserved populations, by enabling remote monitoring, virtual consultations, and timely clinical interventions [76].

PROJECTIONS AND FUTURE CHALLENGES

In the absence of effective large-scale prevention strategies, the global diabetes epidemic is expected to expand further. Projections suggest that by 2045, approximately 783 million individuals worldwide will be living with diabetes, with global healthcare expenditures potentially surpassing USD 1.3 trillion [80]. Low- and middle-income countries (LMICs) are anticipated to face the greatest burden due to rapidly increasing prevalence and constrained healthcare infrastructure.

Addressing this challenge requires a strong focus on minimizing modifiable risk factors, enhancing early detection, and reinforcing healthcare systems to deliver sustained, high-quality diabetes care. Strengthening primary healthcare services, expanding access to affordable treatments, and integrating preventive strategies into public health policies are essential for effective diabetes management and long-term disease control [77].

EPIDEMIOLOGICAL OVERVIEW

India faces a mounting public health crisis due to the rapid rise in diabetes prevalence. As reported in the 11th edition of the International Diabetes Federation (IDF) Diabetes Atlas (2025), approximately 10.5% of Indian adults aged 20–79—equating to nearly 89.8 million people—are living with diabetes [78]. This marks a sharp increase from 32 million in 2000, underscoring the disease's accelerating spread [79].
Prevalence rates vary significantly across states. Southern regions like Tamil Nadu and Kerala, and western states such as Goa and Maharashtra, report higher rates than northern and northeastern areas 80][81]. Urban populations show a prevalence of about 11.2%, compared to 5.2% in rural areas, reflecting disparities in lifestyle, socioeconomic status, and environmental exposures [82].

INCIDENCE AND MORTALITY TRENDS

National epidemiological data spanning 1990 to 2021 indicate a consistent increase in diabetes incidence across India, rising from 162.7 to 264.5 cases per 100,000 population. Among all states, Tamil Nadu reports the highest incidence rates [78]. Diabetes-related mortality has also shown an upward trend, with a more pronounced rise observed in several northern states [83]. Regions characterized by a high prevalence of diabetes combined with limited healthcare resources exhibit the greatest age-standardized mortality rates (ASMR), underscoring disparities in disease burden and access to care.

RISK FACTORS

The Indian population demonstrates heightened susceptibility to diabetes due to a complex interplay of genetic predisposition and environmental influences. Key contributing factors include pronounced insulin resistance, increased central adiposity, and progressive β-cell dysfunction [84]. Rapid urbanization has significantly altered lifestyle patterns, leading to increased intake of energy-dense, processed foods and reduced levels of physical activity, thereby accelerating disease onset and progression [84]. Additionally, socioeconomic status, educational attainment, and accessibility of healthcare services play critical roles in determining diabetes prevalence, early diagnosis, and long-term disease control [85].

DISEASE MANAGEMENT AND HEALTHCARE INFRASTRUCTURE

Delivering comprehensive diabetes care remains a significant challenge within India's healthcare system. Despite the implementation of the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), substantial gaps persist in early detection, treatment adherence, and effective management of diabetes-related complications [86]. These challenges are

particularly pronounced in rural and underserved areas, where access to affordable insulin, glucose monitoring devices, and specialist care is often limited [87].

In response, innovative strategies such as public–private partnerships and digital health interventions have been introduced, including telemedicine services and community-based screening initiatives aimed at improving early diagnosis and continuity of care [88]. However, achieving uniform implementation and scalability of these programs across diverse geographic and socioeconomic settings continues to be a major obstacle [89].

COMPLICATIONS AND DISEASE BURDEN

Diabetes-related complications represent a major contributor to the overall healthcare burden in India. Diabetic retinopathy affects approximately one-third of individuals with diabetes and remains a leading cause of preventable visual impairment [89]. The prevalence of diabetic nephropathy has also increased significantly and is now one of the primary causes of end-stage renal disease (ESRD) in the country [90]. In addition, chronic complications such as peripheral neuropathy, diabetic foot ulcers, and cardiovascular disorders substantially elevate morbidity and mortality, placing considerable strain on both patients and healthcare systems [91].

ECONOMIC AND SOCIAL IMPACT

The financial burden of diabetes in India is substantial, with annual costs—including direct healthcare expenditures and indirect losses due to reduced productivity, long-term disability, and premature mortality—amounting to several tens of billions of U.S. dollars [92]. Beyond economic consequences, diabetes exerts profound social effects, including disease-related stigma, deterioration in quality of life, and increased psychological and caregiving responsibilities for families and caregivers [93].

FUTURE DIRECTIONS AND CHALLENGES

Projections indicate that the number of individuals living with diabetes in India could surpass 120 million by 2030, highlighting the urgency of effective intervention strategies [94]. Addressing this growing burden will require prioritization of preventive measures, enhanced public awareness campaigns, strengthened early detection programs, and the integration of diabetes care services across urban and rural healthcare settings [95].

FUTURE DIRECTIONS AND CHALLENGES

Current projections indicate that India’s diabetic population may exceed 120 million by 2030, underscoring the urgent need for comprehensive preventive and control strategies [94]. To mitigate this growing burden, priority must be given to strengthening preventive healthcare, expanding public awareness initiatives, improving early diagnosis, and ensuring seamless integration of diabetes care services across both urban and rural healthcare systems [95].

Over the last century, the therapeutic landscape for diabetes has evolved remarkably. Management has transitioned from an exclusive dependence on insulin therapy to a diverse range of pharmacological agents designed to address multiple pathophysiological mechanisms of the disease. These treatments aim not only to achieve effective glycemic control but also to minimize complications, improve patient quality of life, and reduce treatment-associated adverse effects [96].

CLASSIFICATION OF ANTIDIABETIC MEDICATIONS

Currently, nine major classes of antidiabetic drugs are used globally [97]:

1. Biguanides (e.g., Metformin)
2. Sulfonylureas
3. Meglitinides
4. Thiazolidinediones (TZDs)
5. Alpha-glucosidase inhibitors
6. DPP-4 inhibitors
7. GLP-1 receptor agonists
8. SGLT2 inhibitors
9. Insulin and its analogs

DRUG CLASSES AND THEIR PROFILES

Biguanides

Metformin is the only biguanide currently used in clinical practice. It lowers blood glucose primarily by decreasing hepatic gluconeogenesis and improving insulin sensitivity in peripheral tissues [98]. Owing to its proven efficacy, favorable safety profile, modest weight reduction, and cardiovascular benefits, it remains the first-line treatment for type 2 diabetes [99]. Gastrointestinal intolerance is frequently reported, whereas lactic acidosis is an uncommon but potentially life-threatening adverse effect [100].

Sulfonylureas

Sulfonylureas act by enhancing insulin secretion from pancreatic β-cells. Although they effectively reduce plasma glucose levels, their use is limited by risks of hypoglycemia and weight gain [101]. Newer-generation agents such as glimepiride have largely supplanted older drugs like chlorpropamide because of a better safety profile [102].

Meglitinides

Meglitinides, including repaglinide and nateglinide, are rapid-acting insulin secretagogues primarily used to manage postprandial hyperglycemia [103]. They allow flexible meal-time dosing but are also associated with hypoglycemia and weight gain [104].

Thiazolidinediones (TZDs)

TZDs such as pioglitazone and rosiglitazone enhance insulin sensitivity through activation of PPARγ receptors in adipose tissue, skeletal muscle, and the liver [105]. While they improve glycemic control and lipid metabolism, their adverse effects include fluid retention, weight gain, and an elevated risk of heart failure [106].

Alpha-glucosidase Inhibitors

Alpha-glucosidase inhibitors like acarbose slow the intestinal breakdown and absorption of carbohydrates, thereby lowering postprandial glucose excursions [107]. Their antihyperglycemic effect is modest, and gastrointestinal adverse effects such as bloating, flatulence, and diarrhea are common [108].

DPP-4 Inhibitors

DPP-4 inhibitors (e.g., sitagliptin and saxagliptin) enhance endogenous incretin activity, resulting in glucose-dependent insulin release and suppression of glucagon secretion [109]. These agents are generally well tolerated, have a low risk of hypoglycemia, and do not significantly affect body weight [110].

GLP-1 Receptor Agonists

GLP-1 receptor agonists such as liraglutide and semaglutide stimulate insulin secretion, inhibit glucagon release, delay gastric emptying, and increase satiety, leading to clinically meaningful weight loss [111]. They also demonstrate cardiovascular risk reduction in patients with established disease. Nausea and gastrointestinal disturbances are the most frequently reported adverse effects [112].

SGLT2 Inhibitors

SGLT2 inhibitors, including canagliflozin and empagliflozin, reduce plasma glucose by increasing renal glucose excretion via an insulin-independent mechanism [113]. In addition to glycemic control, they provide cardiovascular and renal benefits, though they may increase the risk of genital and urinary tract infections and, rarely, diabetic ketoacidosis [114].

Insulin Therapy

Insulin therapy is indispensable for patients with type 1 diabetes and is often required in later stages of type 2 diabetes. Various formulations are available, including rapid-acting, long-acting, and premixed preparations [115]. Hypoglycemia and weight gain remain the major limitations of insulin use [116].

BENEFITS OF ANTIDIABETIC MEDICATIONS

• Significant improvement in glycemic control, including reductions in blood glucose levels and HbA1c, thereby decreasing the incidence of microvascular complications [117]
• Cardiovascular risk reduction observed with certain drug classes, notably SGLT2 inhibitors and GLP-1 receptor agonists [118]
• Favorable effects on body weight, particularly weight loss associated with GLP-1 receptor agonists and metformin therapy [119]
• Renoprotective effects, especially evident with the use of SGLT2 inhibitors [120]

LIMITATIONS AND ADVERSE EFFECTS

• Increased risk of hypoglycemia is associated with insulin secretagogues such as sulfonylureas and meglitinides, as well as with insulin therapy [121]
• Metformin and alpha-glucosidase inhibitors commonly cause gastrointestinal adverse effects, including nausea, diarrhea, and abdominal discomfort [122]
• Thiazolidinediones are linked to fluid retention and may exacerbate or precipitate heart failure in susceptible patients [123]
• SGLT2 inhibitors are associated with a higher incidence of urinary tract and genital infections due to increased glycosuria [124]
• The high cost and requirement for injectable administration limit the widespread adoption of GLP-1 receptor agonists [125]

NEW RESEARCH DRUGS IN DIABETES MELLITUS – ADVANCES AND CLINICAL IMPACT IN 2025 INTRODUCTION

Diabetes management is entering a rapidly evolving era, driven by the development of innovative pharmacologic agents, novel delivery platforms, and biologic therapies that target underlying disease mechanisms. The expanding research pipeline aims not only to improve glycemic control and reduce long-term complications but also to modify disease progression and potentially induce remission, particularly in type 1 diabetes (T1D) [126].

STEM CELL AND BETA-CELL REPLACEMENT THERAPIES

Recent advances emphasize the restoration of endogenous insulin secretion through beta-cell regeneration and replacement strategies. A prominent example is Vertex Pharmaceuticals' Zimislecel (VX-880), a stem cell–derived islet cell therapy that has demonstrated promising results in phase 3 trials, with some T1D patients achieving sustained insulin independence [127].

Encapsulation-based approaches, such as CRISPR Therapeutics' VCTX-211, are designed to protect implanted cells from immune attack, potentially reducing or eliminating the need for long-term immunosuppression [128]. Additional platforms, including ViaCyte's PEC-Direct and PEC-Encap devices, utilize semi-permeable membranes to support pancreatic progenitor cell survival and function [129]. Similarly, Sernova's Cell Pouch™—a bioengineered implantable system—has shown encouraging outcomes in early-stage clinical studies [130].

IMMUNE MODULATION AND DISEASE MODIFICATION

Immunotherapeutic strategies are increasingly recognized for their role in altering disease progression in T1D. Teplizumab (Tzield™) has emerged as the first FDA-approved therapy shown to delay the onset of stage 2 T1D by preserving residual beta-cell activity [131]. Its regulatory approval in regions such as China and the United Kingdom highlights growing global acceptance of immune-based diabetes interventions [132].

Additionally, verapamil, a calcium channel blocker, has demonstrated potential benefits in newly diagnosed T1D patients by reducing endoplasmic reticulum stress and preserving beta-cell function [133].

NEW ORAL AGENTS AND COMBINATION THERAPIES

Oral formulations of GLP-1 receptor agonists, notably semaglutide (Rybelsus), have enhanced patient convenience while maintaining efficacy in glycemic control, weight reduction, and cardiovascular risk mitigation [134].

Novel compounds such as PATAS target insulin resistance at the adipocyte level and may play a role in preventing type 2 diabetes (T2D) and associated metabolic disorders [135]. Microbiome-based approaches—including fecal microbiota transplantation and genetically engineered gut bacteria—are also being explored, though their clinical utility remains in early investigational stages [136].

Tirzepatide, a dual GLP-1/GIP receptor agonist, has consistently demonstrated superior reductions in HbA1c and body weight compared with single-incretin therapies in patients with T2D [137].

INNOVATIONS IN INSULIN DELIVERY

Significant progress is being made toward improving insulin administration. Research efforts include the development of needle-free delivery systems, ultra-rapid-acting insulin analogs, and oral insulin formulations utilizing nanocarrier technologies to enhance gastrointestinal stability and hepatic targeting, thereby reducing hypoglycemia risk [138].

Artificial pancreas systems that combine continuous glucose monitoring with automated insulin delivery are also advancing, offering improved glycemic control and enhanced quality of life for insulin-dependent patients [139].

CHALLENGES AND SAFETY CONSIDERATIONS

Despite these advancements, notable challenges persist. Immunotherapies such as teplizumab require careful patient selection and close monitoring due to potential immune-related adverse effects [140]. Stem cell–based interventions remain limited by high costs, risks of immune rejection, and dependence on immunosuppressive therapy [127].

Oral insulin formulations continue to face obstacles related to absorption and bioavailability [128]. Furthermore, while GLP-1 receptor agonists and SGLT2 inhibitors offer substantial benefits, they are associated with gastrointestinal disturbances, urinary tract infections, and rare but serious adverse events such as pancreatitis and diabetic ketoacidosis [129].

REFERENCES

1) American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S19–S40.
2) Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001 Dec 13;414(6865):782-7.
3) Mering JV, Minkowski O. Diabetes after pancreas extirpation. Beitr Klin TuberkSpezifischeTuberkulose-Forsch. 1889;10:1-248.
4) Bliss M. The discovery of insulin. University of Chicago Press; 1982.
5) International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: IDF; 2021. Available from: https://diabetesatlas.org.
6) Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980. Lancet. 2011 Jul 9;378(9785):31-40.
7) Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clin Diabetes. 2008 Jul;26(2):77-82.
8) American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2024 Jan;47(Suppl 1):S14-S31.
9) Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2024 Mar 15;383(9911):69-82.
10) DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835.

11) Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001 Sep 13;345(11):790-7.

12) Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005 Mar;115(3):485-91.

13) Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965 Mar;14(2):619-33.

14) Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014 Mar 22;383(9922):1068-83.

15) Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25.

16) American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S1-S259.

17) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003 Jan;26 Suppl1:S5-20.

18) Anjana RM, Deepa M, Pradeepa R, et al. Prevalence of diabetes and prediabetes in India. Lancet Diabetes Endocrinol. 2017 Aug;5(8):585-596.

19) Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Lancet. 2010 Jan 30;375(9712):408-418.

20) Saha S, Mallik S, Chowdhury S. Diabetes epidemic in India. J Soc Health Diab. 2013;1(1):14-18.

21) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.

22) Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA. 2015 Jul 14;314(2):187-99.

23) Zinman B, Wanner C, Lachin JM, et al. Empagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.

24) Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017 May;13(5):268-277.

25) American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S19–S40.

26) Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2024 Mar 15;383(9911):69-82.

27) Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965 Mar;14(2):619-33.

28) Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct;38(10):1964-74.

29) DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018 Mar 3;391(10138):2449-2462.

30) Pihoker C, Gilliam LK, Hampe CS, Lernmark Å. Autoantibodies in diabetes. Diabetes. 2005 Mar;54 Suppl2:S52-61.

31) DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835.

32) Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001 Sep 13;345(11):790-7.

33) American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2024. Diabetes Care. 2024 Jan;47(Suppl 1):S14-S31.

34) Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016 Apr;26(4):364-73.

35) Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014 Mar 22;383(9922):1068-83.

36) Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to Management of Hyperglycemia in Type 2 Diabetes, 2018. Diabetes Care. 2020 Feb;43(2):487-493.

37) American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S320-S327.

38) Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005 Mar;115(3):485-91.

39) Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009 May 23;373(9677):1773-9.

40) International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010 Mar;33(3):676-82

41) Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2024 Mar 15;383(9911):69-82.

42) Brutsaert EF. Diabetes Mellitus (DM) - Hormonal and Metabolic Disorders. MSD Manuals. 2025 Apr 9 [cited 2025 Oct 29]. Available from: https://www.msdmanuals.com/home/hormonal-and-metabolic-disorders/diabetes-mellitus-dm-and-disorders-of-blood-sugar-metabolism/diabetes-mellitus-dm

43) Mayo Clinic Staff. Diabetes - Symptoms and causes. Mayo Clin Proc. 2024 Mar 26;99(3):508-512.

44) Ganesh Diagnostic. Symptoms of Diabetes: A Comprehensive Guide. Ganesh Diagn J. 2025 Sep;24(3):145-153.

45) Fisher L, Hessler DM, Polonsky WH. Understanding the symptoms and signs of diabetes. Diabetes Care. 2019 Oct;42(10):1692-1702.

46) American Diabetes Association. Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024 Jan;47(Suppl 1):S1-S259.

47) CDC. Symptoms of Diabetes. MMWR Morb Mortal Wkly Rep. 2024 Jul 17;73(29):455-460.

48) Raman R, Rani PK. Diabetic retinopathy: pathophysiology and clinical manifestations. Indian J Ophthalmol. 2025 Apr;73(4):414-423.

49) Mayo Clinic Staff. Diabetes-related infections. Mayo Clin Proc. 2024 May;99(5):857-863.

50) National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes complications. Diabetes Care. 2020 Jan;43(1):7-16.

51) Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity and treatments. Diabetes Care. 2010 Oct;33(10):2285-93.

52) Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.

53) WebMD. Type 2 diabetes symptoms. WebMD Healthcare. 2024;12(4):200-209.

54) NIH. Acanthosis nigricans and insulin resistance. J Clin Endocrinol Metab. 2023 Dec;108(12):3259-3265.

55) Buchanan TA, Xiang AH. Gestational diabetes mellitus: risks and management. J Clin Invest. 2005 Mar;115(3):485-91.

56) Osmosis. Signs and symptoms of diabetes mellitus. Osmosis J. 2025 Mar;15(3):25-37.

57) International Diabetes Federation. IDF Diabetes Atlas 11th edition. Brussels: IDF; 2025.

58) Duncan BB, Schmidt MI, Zhang L, et al. Global prevalence and projections of diabetes. Nephrol Dial Transplant. 2025 Aug 27;doi:10.1093/ndt/gfaf177.

59) Ong KL, Cheung BM, Man YB, et al. Global trends in diabetes prevalence: 2021–2050 projections. Lancet Diabetes Endocrinol. 2023;11(3):223-33.

60) World Health Organization. Diabetes fact sheet. Geneva: WHO; 2024 Nov 13.

61) IDF Diabetes Atlas | Global Diabetes Data & Statistics [internet]. Brussels: IDF; 2025 [cited 2025 Oct 29]. Available from: https://diabetesatlas.org

62) International Diabetes Federation. IDF Africa Region Report. IDF; 2025.

63) IDF. Diabetes causes 3.4 million deaths annually worldwide. Brussels: IDF; 2024.

64) Kannel WB. Cardiovascular disease in diabetes. JAMA. 2019;321(9):835-40.

65) Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clin Diabetes. 2008;26(2):77-82.

66) IDF Diabetes Atlas 2025. Epidemiological facts. Brussels: IDF; 2025.

67) American Diabetes Association. Economic costs of diabetes in the US. Diabetes Care. 2025;48(7):152-62.

68) IDF Diabetes Atlas. Global healthcare expenditures on diabetes. 2025.

69) WHO Global Health Expenditure Database. Geneva; 2023.

70) Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015. Diabetes Care. 2015;38(1):140-9.

71) Leong A, Teo KK, Rangarajan S, et al. Physical activity and diabetes control. Lancet Diabetes Endocrinol. 2023;11(6):510-519.

72) Telemedicine Society. Diabetes care telemedicine innovations. 2025 Annual Report.

73) Zhou B, Bentham J, Di Cesare M, et al. Worldwide trends in diabetes risk factors. Lancet. 2018;392(10155):1219-29.

74) Sobngwi E, Mbanya JC. Diabetes in Sub-Saharan Africa. Lancet Diabetes Endocrinol. 2022;10(5):299-307.

75) Papanas N, Ziegler D. Diabetes in Europe and America: management strategies. Diabetes Metab Res Rev. 2024;40(5):e3304.

76) International Diabetes Federation. Diabetes Atlas Projections 2025-2045. Brussels: IDF; 2025.

77) Gaziano TA, Bitton A, Anand S, et al. Prevention of diabetes complications: a global challenge. Lancet. 2015;386(9995):2249-58.

78) Duncan BB, Schmidt MI, Zhang L, et al. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections. Nephrol Dial Transplant. 2025 Aug 27;doi:10.1093/ndt/gfaf177.

79) JAPI. The unrelenting epidemic of diabetes in India. J Assoc Physicians India. 2025 Apr;73(5):12-20.

80) National Family Health Survey 5. Ministry of Health & Family Welfare, Government of India; 2021.

81) Kalkonde YV, et al. Urban-rural differences in diabetes prevalence in India. Indian J Endocrinol Metab. 2024;28(6):675–683.

82) India Diabetes Alliance. Diabetes prevalence in urban and rural India: 2024 Report. Public Health Foundation of India.

83) Chauhan S, Kumar V, Pujari S, et al. Rising incidence and mortality of diabetes in India (1990-2021). Diabetes Care J. 2025;48(3):335–342.

84) Misra A, Ganda OP. Diabetes in South Asians: phenotype, clinical presentation, and management challenges. Lancet Diabetes Endocrinol. 2024 Jun;12(6):717–730.

85) Mohan V, Deepa M. Changing dietary and physical activity patterns in urban India: impact on diabetes prevalence. Asia Pac J Clin Nutr. 2024;33(1):43–52.

86) Rajput R, Singh MM. Socioeconomic and educational determinants of diabetes awareness and control in India. Diabetes Epidemiol Control. 2025;14(2):101–109.

87) Ministry of Health and Family Welfare. National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke. Annual Report 2025. New Delhi.

88) Iyer PU, et al. Challenges in diabetes care delivery in rural India. Indian J Public Health. 2025;69(1):55-61.

89) Narayanan N, et al. Digital health interventions in diabetes: opportunities in India. J Med Internet Res. 2025 Mar;27(3):e23457.

90) WHO India. Diabetes Care and Management Report 2024.

91) Raman R, Rani PK, Ganesan S, Sharma T. Prevalence of diabetic retinopathy in India: a systematic review. Indian J Ophthalmol. 2025 Apr;73(4):414-423.

92) Parameswaran S, et al. Diabetes nephropathy trends in India. Indian J Nephrol. 2024;34(5):337-343.

93) Narayan KMV et al. Cardiovascular burden in Indian diabetic patients. Circulation. 2024;151(3):121-130.

94) Duggal R, Gupta M. Economic impact of diabetes in India. Indian J Endocrinol Metab. 2025;29(2):180-187.

95) Patel V, et al. Social and psychological impact of diabetes in India. Lancet Glob Health. 2024;12(11):e1402–e1406.

96) Antar SA, Chaudhary A, et al. Diabetes mellitus: Classification, mediators, and drug therapies. Curr Med Chem. 2023;30(4):394-411.

97) Feingold KR. Oral and Injectable (Non-Insulin) Pharmacological Agents for Type 2 Diabetes Mellitus. Endotext. 2024 Sep 10.

98) Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566-76.

99) American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S125-S138.

100) Salpeter SR, et al. Risk of lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jun 16;(4):CD002967.

101) Khunti K, et al. Sulfonylureas and risk of hypoglycemia. Diabetes ObesMetab. 2020;22(1):1-8.

102) Holstein A, et al. Safety of modern sulfonylureas. Diabetes Technol Ther. 2010;12(6):447-55.

103) Ristic S, et al. Meglitinides: clinical review of their use in type 2 diabetes mellitus. Drugs. 2004;64(13):1401-24.

104) Hanefeld M. Risk of hypoglycemia with meglitinides. Diabetes Educ. 2001;27(6 Suppl):25-9.

105) Neylon OM, Maclaughlin EJ. Thiazolidinediones: an update on their role in the management of type 2 diabetes mellitus. Ther Adv Endocrinol Metab. 2010;1(3):113-25.

106) Nesto RW, et al. Thiazolidinediones and risk of heart failure. Circulation. 2003;108(21):2941-8.

107) van de Laar FA, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003639.

108) Van de Laar FA. Side-effects of alpha-glucosidase inhibitors. Diabetes Care. 2003;26(7):2169-70.

109) Gallwitz B. DPP-4 inhibitors: clinical aspects. Int J Clin Pract. 2011;65(4):354-68.

110) Kothny W, et al. Safety evaluation of DPP-4 inhibitors: overview. Diabetes ObesMetab. 2015;17(8):667-76.

111) Nauck MA, Meier JJ. Incretin-based therapies: GLP-1 receptor agonists and DPP-4 inhibitors in type 2 diabetes. Lancet Diabetes Endocrinol. 2018.

112) Marso SP, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.

113) Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28.

114) Puckrin R, et al. Risk of ketoacidosis with SGLT2 inhibitors. Drug Saf. 2020;43(5):451-60.

115) Owens DR. Insulin preparations. Diabet Med. 2002;19 Suppl 3:12-8.

116) Hirsch IB. Hypoglycemia and weight gain with insulin therapy. J Clin Endocrinol Metab. 2005;90(2):523-9.

117) UK Prospective Diabetes Study Group. Intensive blood-glucose control. Lancet. 1998;352(9131):837-53.

118) Gerstein HC, et al. Cardiovascular safety of diabetes drugs. Nat Rev Cardiol. 2020;17(9):465-79.

119) Pi-Sunyer X, et al. Weight loss with GLP-1 receptor agonists. Lancet Diabetes Endocrinol. 2018;6(6):451-60.

120) Neuen BL, et al. SGLT2 inhibitors and renal protection. Kidney Int. 2019;96(1):26-39.

121) UKPDS Group. Sulfonylureas effects on blood glucose. Diabetes. 1998;47(2):374-83.

122) Dowling RJ, et al. Metformin gastrointestinal side effects. Aliment Pharmacol Ther. 2016; 43(3):260-70.

123) Takahashi N, et al. Thiazolidinediones and heart failure risk. Circ J. 2018;82(3):758-766.

124) Dave CV, et al. Urinary tract infections with SGLT2 inhibitors. Diabetes Care. 2019;42(7):e110-e111.

125) Pratley RE, et al. GLP-1 receptor agonists limits. Diabetes Care. 2017;40(10):e135-e139.

126) Type 1 Diabetes Research Breakthroughs to Watch in 2025. Type1Strong.org [internet]. 2025 Sep 28 [cited 2025 Oct 29]

127) Vertex Pharmaceuticals. Zimislecel (VX-880) Phase 3 Trial Results. Vertex.com; 2025 Jun [cited 2025 Oct 29.

128) CRISPR Therapeutics. VCTX-211 Clinical Trial Update. CRISPRTx.com; 2025 Jan [cited 2025 Oct 29].

129) ViaCyte, Inc. PEC-Direct and PEC-Encap Trials. Viacyte.com; 2025.

130) Sernova Corp. Cell Pouch™ Phase 1/2 Clinical Trial. Sernova.com; 2025 Oct [cited 2025 Oct 29].

131) Herold KC, et al. Teplizumab for prevention of type 1 diabetes. N Engl J Med. 2019;381(7):603-613.

132) NMPA China approves Teplizumab (Tzield™). National Medical Products Administration; 2025 Sep.

133) Ver-A-T1D Study Group. Verapamil SR preserves β-cell function in T1D. Diabetes Care. 2025;48(3):456-463.

134) Davies M, et al. Efficacy and safety of oral semaglutide in T2D. Lancet Diabetes Endocrinol. 2020;8(3):202-210.

135) Monash University. PATAS clinical development update. Monash.edu; 2025.

136) van Nood E, et al. Fecal microbiota transplantation for insulin resistance. N Engl J Med. 2020;382(21):2008-9.

137) Frias JP, et al. Efficacy of Tirzepatide in T2D. Lancet. 2021;397(10287): 1519-28.

138) Sydney University Research. Nanocarrier oral insulin study. Sydney.edu.au; 2025.

139) Kovatchev BP, et al. Artificial pancreas advances. Diabetes Technol Ther. 2025;27(2):75-84.

140) Atkinson MA, Bluestone JA. Immunotherapy in T1D: progress and pitfalls. Lancet. 2024; 393(10189):211-222.